FDA approves 6-month HIV prevention shot
Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more than 99.9 percent effective among participants.
Gilead's product Yeztugo, a form of lenacapavir, was approved for reducing the risk of sexually acquired HIV in adults and adolescents when injected twice a year. Lenacapavir is also marketed as Sunlenca, administered orally or through injection, as a treatment for HIV/AIDS in combination with other drugs. The drug is solely manufactured by Gilead.
There are currently three available HIV PrEP options: two oral pills taken daily — Truvada and Descovy — and a long-acting injection called Apretude administered every two months.
'Yeztugo could be the transformative PrEP option we've been waiting for — offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic,' Carlos del Rio, co-Director of the Emory Center for AIDS Research, said in a statement shared by Gilead.
In a Phase 3, double-blind, randomized study, there were only two HIV infections among 2,179 participants who received Yeztugo subcutaneous injections twice a year.
Lenacapavir is currently not approved for HIV prevention outside of the U.S., though it is approved for treating HIV in several countries.
'In the U.S., Gilead is working closely with insurers, healthcare systems and other payers with the goal of ensuring broad insurance coverage for Yeztugo,' the company said in a statement. 'Additionally, for eligible commercially insured individuals with commercial insurance, Gilead's Advancing Access® Co-Pay Savings Program will reduce out-of-pocket costs to as little as zero dollars.'
Carl Schmid, Executive Director of the HIV+Hepatitis Policy Institute, called the approval a 'monumental advance in HIV prevention.'
'Long-acting PrEP is now not only effective for up to six months but also improves adherence and will reduce HIV infections—if people are aware of it and payers, including private insurers, cover it without cost-sharing as a preventive service,' said Shmid.
'Recent actions by the Trump administration to decimate HIV prevention jeopardize access to preventive measures such as PrEP,' he added.
'In fact, the president's budget zeroes out all CDC HIV prevention and surveillance funding, hampering our nation's ability to make people aware of and access new HIV prevention measures. Dismantling these programs means that there will be a weakened public health infrastructure and much less HIV testing, which is needed before a person can take PrEP.'
The Hill has reached out to the White House for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
37 minutes ago
- Epoch Times
FDA Approves HIV-Prevention Drug That Nearly Eliminated the Virus's Spread in Clinical Trials
Gilead Sciences announced June 18 that the Food and Drug Administration (FDA) has approved its twice-a-year shot to prevent HIV, with company executives touting the medication as a 'very real opportunity' at ending the HIV epidemic. In a
Boston Globe
an hour ago
- Boston Globe
Boston transit operator to borrow $939 million as deficit looms
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up HEALTH CARE Advertisement The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it A vial of lenacapavir, an injectable HIV prevention drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, which was one of the sites for Gilead's lenacapavir drug trial. Nardus Engelbrecht/Associated Press The United States has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions — although it's unclear how many in the United States and abroad will get access to the powerful new option. While a vaccine to prevent HIV still is needed, some experts say the shot made by Gilead Sciences — a drug called lenacapavir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take. Condoms help guard against HIV infection if used properly but what's called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is increasingly important. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills. — ASSOCIATED PRESS Advertisement DEALS Nippon Steel completes its acquisition of US Steel A view of the United States Steel Mon Valley Works Clairton Plant, in Clairton, Pa. Ted Shaffrey/Associated Press Nippon Steel has completed its acquisition of US Steel, the companies said Wednesday, more than a year after it was first announced. Soon after Nippon announced its plans to acquire US Steel in December 2023, the company, based in Pennsylvania, a swing state in the presidential election, became part of a game of political football. The powerful United Steelworkers union pushed back against the deal, and President Biden blocked it over national security concerns. Last month, President Donald Trump, who had opposed the deal while he was on the campaign trail, said he had approved a transaction that granted the White House a golden share in the company, giving it extraordinary control over the new company as part of a national security agreement. Trump and the companies have frequently referred to the deal as a partnership over the past several weeks, fueling mystery on Wall Street and in Washington over its nature. — NEW YORK TIMES SOCIAL MEDIA Trump will sign an order extending deadline for TikTok's Chinese owner to sell app The TikTok app page on a smartphone in New York on Jan. 15. Gabby Jones/Bloomberg President Trump will sign an executive order this week to extend a deadline for TikTok's Chinese owner to divest the popular video sharing app, the White House announced Tuesday. Trump had signed an order in early April to keep TikTok running for an additional 75 days after a potential deal to sell the app to American owners was put on ice. 'As he has said many times, President Trump does not want TikTok to go dark,' White House press secretary Karoline Leavitt said in a statement. 'This extension will last 90 days, which the Administration will spend working to ensure this deal is closed so that the American people can continue to use TikTok with the assurance that their data is safe and secure.' It will be the third time Trump has extended the deadline. — ASSOCIATED PRESS Advertisement LEGAL Purdue Pharma's $7 billion opioid settlement could advance soon after states back it OxyContin pills arranged for a photo at a pharmacy in Montpelier, Vt. Toby Talbot/Associated Press OxyContin maker Purdue Pharma's latest plan to settle thousands of lawsuits over the toll of opioids could soon move forward after every US state involved agreed to it. A judge on Wednesday said he planned to issue a ruling on Friday on a plan for local governments and individual victims to vote on it. Government entities, emergency room doctors, insurers, families of children born into withdrawal from the powerful prescription painkiller, individual victims and their families, and others would have until Sept. 30 to vote on whether to accept the deal, which calls for members of the Sackler family who own the company to pay up to $7 billion over 15 years. The settlement is a way to avoid trials with claims from states alone that total more than $2 trillion in damages. Thousands of local governments and other groups have also sued Purdue. If approved, the settlement would be among the largest in a wave of lawsuits over the past decade as governments and others sought to hold drugmakers, wholesalers, and pharmacies accountable for the opioid epidemic that started rising in the years after OxyContin hit the market in 1996. The other settlements together are worth about $50 billion, and most of the money is to be used to combat the crisis. — ASSOCIATED PRESS Advertisement TECH WhatsApp denies Iran's claim that it is spying for Israel A WhatsApp icon is displayed on an iPhone. Martin Meissner/Associated Press Iran's state broadcaster Tuesday urged people to remove WhatsApp from their phones, claiming that the messaging app was collecting user information and sending it to Israel as the two countries trade military strikes. 'WhatsApp and Instagram are collecting information about individuals and are providing the Zionist enemy with their last known location and communications, tagged with the names of individuals,' the Iranian state television network said, referring to Israel. It did not provide evidence for its claims. WhatsApp, in a statement Tuesday, said the allegations were false. 'We're concerned these false reports will be an excuse for our services to be blocked at a time when people need them the most,' the statement said. 'All of the messages you send to family and friends on WhatsApp are end-to-end encrypted, meaning no one except the sender and recipient has access to those messages, not even WhatsApp.' — NEW YORK TIMES ARTIFICIAL INTELLIGENCE Amazon CEO Jassy says AI will reduce its corporate workforce in the next few years Andy Jassy, chief executive officer of Inc., at an event in New York on Feb. 26. Michael Nagle/Bloomberg Amazon CEO Andy Jassy anticipates generative artificial intelligence will reduce its corporate workforce in the next few years as the online giant begins to increase its usage of the technology. 'We will need fewer people doing some of the jobs that are being done today, and more people doing other types of jobs,' Jassy said in a message to employees. 'It's hard to know exactly where this nets out over time, but in the next few years, we expect that this will reduce our total corporate workforce as we get efficiency gains from using AI extensively across the company.' — ASSOCIATED PRESS AUTOMOTIVE Honda recalls more than 259,000 cars across the US due to brake pedal issue The Honda logo. Gene J. Puskar/Associated Press Honda is recalling more than 259,000 of its cars across the United States due to a problem that can cause the brake pedal to shift out of position, potentially interfering with a driver's ability to stop or slow down. According to documents published by the National Highway Traffic Safety Administration, the recall covers certain Honda Pilots between model years 2023 and 2025 — as well cars under the automaker's luxury Acura brand: 2021-2025 Acura TLX and 2023-2025 Acura MDX vehicles. As a remedy, Honda says authorized dealers will inspect the vehicles covered by this recall and replace the brake pedal assembly if necessary, free of charge. Per the NHTSA's report, the company estimates 1 percent of these vehicles have this issue. — ASSOCIATED PRESS Advertisement AVIATION Families of 737 crash victims urge rejection of Boeing deal Family members of victims of the Ethiopian Airlines Boeing 737 MAX 8 crash held a sign as President and CEO of Boeing Kelly Ortberg testified before the Senate Commerce, Science, and Transportation Committee on April 2 in Washington, D.C. Win McNamee/Getty Family members of people killed in two fatal crashes of Boeing Co.'s 737 Max jets urged a federal judge to reject a proposed deal the company reached with US prosecutors that would allow the planemaker to avoid a criminal charge. Lawyers for 15 families argued Boeing should stand trial for criminal conspiracy as the government had originally planned, to hold the company more accountable for the deaths of 346 people, according to a court filing Wednesday. The US Justice Department in May asked US District Judge Reed O'Connor in Fort Worth to dismiss the case as part of a proposed settlement reached with Boeing. Under the deal, the planemaker agreed to pay more than $1.1 billion in fees and fines, while taking steps to strengthen internal quality and safety measures. In return, the company will avoid criminal prosecution. — BLOOMBERG NEWS
UPI
an hour ago
- UPI
FDA approves long-lasting HIV-prevention drug
1 of 2 | A man photographs a portion of the AIDS quilt during an HIV/AIDS rally on the National Mall in Washington, D.C., in 2021. The Food and Drug Administration has said that it has approved a new drug that could prevent HIV infections with just two shots every year. File Photo by Kevin Dietsch/UPI | License Photo June 18 (UPI) -- The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and possibly eradicate the disease. The drug's scientific name is lenacapavir and it will be marketed as Yeztugo, which requires one injection every six months to maintain its effectiveness in preventing HIV infections. Other drugs exist that also prevent HIV, but they require daily dosages in pill form and have not significantly affected the disease on a global level. "We're on the precipice of now being able to deliver the greatest prevention option we've had in 44 years of this epidemic," AVAC executive director Mitchell Warren told the New York Times. AVAC is an anti-HIV organization. He said recent funding cuts by the Trump administration will make it hard to distribute the drug globally. "It's as if that opportunity is being snatched from out of our hands by the policies of the last five months," Warren said. Gilead Sciences is producing the drug, which is the second long-lasting HIV prevention drug available. The other option is cabotegravir, which is sold under the brand name Apretude and requires an injection every two months. About 21,000 Americans use Apretude, while about 500,000 use daily oral medications to prevent HIV. Clinical trials showed most participants who received two shots of lenacapavir every year had nearly full protection against HIV. More than 39,000 people in the United States contracted HIV in 2023, which carries an estimated lifetime treatment cost of $1.1 million per patient, Gilead Chairman and Chief Executive Officer Daniel O'Day told the New York Times. Lenacapavir already is being prescribed to treat people with HIV infections that resist other medications and at an annual cost of $42,000 per patient, but most patients don't pay the full cost. Health insurance coverage and patient-assistance programs would cover the cost for most people using lenacapavir, according to Gilead. The cost for oral pills taken daily is just $1 per pill, while Apretude carries an annual cost of about $24,000. Proposed funding reductions for Medicaid and the President's Emergency Program for AIDs Relief, commonly called PEPFAR, might greatly reduce access to the drug, according to advocacy groups. The PrEP oral treatment still would be available, but it does not work for many people, Health Gap Executive Director Asia Russell told the New York Times.
